• Kai Gao, Yan-Ping Song, Anna Song, Hao Chen, Lin-Tao Zhao, and Hai-Wang Zhang.
• Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang.
• Medicine (Baltimore). 2020 Feb 1; 99 (8): e19158e19158.

BackgroundShenmai injection (SMI) is a Traditional Chinese Medicine patent prescription consisting of extractions from ophiopogonis radix and ginseng radix rubra. Clinical studies showed that SMI combined with conventional medicine treatment (CMT) can enhance the therapeutic efficacy for dilated cardiomyopathy (DCM). However, there is still a lack of comprehensive and systematic evidence, which urgently requires us to verify its therapeutic efficacy. Hence, we provide a protocol for systematic review and meta-analysis.MethodsThe systematic search on the MEDLINE/PubMed, China National Knowledge Infrastructure (CNKI), Wanfang database, VIP database, the Cochrane Library, Embase and Chinese Biomedical Database (CBM) in Chinese and English language with dates ranging from the earliest record to August 8, 2019. Next, the quality of each trial was assessed according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions. Then, the outcome data were recorded and pooled by RevMan 5.3 software.ResultsThe systematic review and meta-analysis aims to review and pool current clinical outcomes of SMI for the adjuvant treatment of DCM.ConclusionThis study will provide a high-quality evidence of SMI for the adjuvant treatment on DCM patients.Prospero Registration NumberCRD42019146369.

21 keywords...

hide…